Iressa Eyed As Worthy Drug Candidate For Companion Diagnostic
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca maintains a "laissez-faire" approach to an Iressa lung cancer drug/diagnostic combination, DxS CEO Little says. Genzyme asserts use of DakoCytoMation's HercepTest in the pivotal study would have sped FDA approval of Herceptin.